Marilena Vrana Joins ARMONIA 2025 in Athens to Discuss Plasma Access
Marilena Vrana, Vice President at the Plasma Protein Therapeutics Association (PPTA) Europe, shared on LinkedIn:
”Why does the dependency of Europe on the US for plasma for fractionation persist? What does it mean for patient access and health-systems resilience?
These are some of the questions we will explore at ARMONIA’s 1st Conference on Primary Immunodeficiencies on 12 November in Athens, where I will represent PPTA Europe, Plasma Protein Therapeutics Association (PPTA).
Plasma and plasma-derived therapies availability is a public-health issue with very real consequences for people whose lives depend on them. I look forward to a forward-looking, evidence-based discussion with all stakeholders present.
CU in Athens.
12 November 2025
Wyndham Grand Athens
Agenda here.”
Keep up with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal